A 224% year-over-year revenue jump is the kind of number that reframes a company’s strategic position overnight, and Syndax’s first quarter puts revumenib in a different competitive conversation than it occupied twelve months ago. Combined net sales of Revuforj and Niktimvo crossed $104 million in a single quarter, with revumenib alone generating $48.9 million — a 144% increase over Q1 2025 — on the strength of accelerating NPM1m AML adoption. That sequential growth of 11% quarter-over-quarter is more telling than the year-over-year figure; it signals a product still climbing its commercial curve, not one pulling forward demand.
The transplant-bridge data embedded in this update carries real strategic weight. Nearly half of R/R KMT2A-translocated patients treated with revumenib are proceeding to stem cell transplant, up sharply from a prior 33% estimate. This matters commercially because it creates a built-in post-transplant maintenance population — patients who already demonstrated benefit, have a prescriber relationship, and face documented relapse risk. Syndax is explicitly modeling longer average treatment duration around this dynamic, which is a structural revenue argument, not a volume argument. It shifts the unit economics without requiring a single new label expansion.
The pipeline pressure on Pfizer’s mavelertinib and Kura’s ziftomenib is real. Syndax is running two pivotal frontline trials simultaneously — EVOLVE-2 in VEN/AZA-ineligible patients and REVEAL-ND in intensive chemotherapy-eligible NPM1m AML — while simultaneously accumulating combination data with venetoclax, gilteritinib, and intensive chemotherapy regimens. The breadth of that evidence base is a deliberate moat-building strategy: whoever owns the frontline menin inhibitor data package first controls physician habit formation in a disease where treatment algorithms calcify quickly. The HOVON network partnership on EVOLVE-2 extends Syndax’s reach into European academic centers that competitor programs have not yet penetrated at that scale.
Niktimvo’s axatilimab franchise adds an entirely separate growth vector, with Phase 2 topline data due in Q4 2026 for both IPF and newly diagnosed chronic GVHD — indications with dramatically larger patient populations than the current label. The single number to track between now and year-end is the REVEAL-ND enrollment velocity: if Syndax secures full enrollment ahead of Kura’s KOMET-007 readout timeline, the frontline menin race ends before a competitor can complete it.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
